NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

HLVX

HilleVax Inc

Jun 23 • 04:00PM ET

1.88

Dollar change +0.02
Percentage change 1.08	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA PFE JNJ AZN BNTX GSK NVAX DVAX VXRT ALT

| Held by: IWM VTI VXF IWN VTWO VHT IWC IWO RSSL VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.16	Insider Own	54.53%	Shs Outstand	50.10M	Perf Week	1.62%
Market Cap	94.26M	Forward P/E	-	EPS next Y	-0.60	Insider Trans	-0.13%	Shs Float	22.80M	Perf Month	-1.05%
Enterprise Value	-41.24M	PEG	-	EPS next Q	-0.14	Inst Own	34.42%	Short Float	7.73%	Perf Quarter	11.90%
Income	-106.50M	P/S	-	EPS this Y	80.67%	Inst Trans	-2.63%	Short Ratio	6.81	Perf Half Y	-1.05%
Sales	0.00M	P/B	0.62	EPS next Y	-4.31%	ROA	-43.20%	Short Interest	1.76M	Perf YTD	-9.18%
Book/sh	3.01	P/C	0.59	EPS next 5Y	38.88%	ROE	-54.64%	52W High	15.25 -87.67%	Perf Year	-85.31%
Cash/sh	3.18	P/FCF	-	EPS past 3/5Y	4.05% -166.47%	ROIC	-62.15%	52W Low	1.34 40.30%	Perf 3Y	-80.23%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	1.28% 1.95%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	34.55%	Oper. Margin	-	ATR (14)	0.08	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	25.32	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.22	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	25.32	EPS Q/Q	87.45%	SMA20	-1.44%	Beta	0.74	Target Price	2.00
Payout	-	Debt/Eq	0.16	Sales Q/Q	-	SMA50	0.51%	Rel Volume	0.58	Prev Close	1.86
Employees	14	LT Debt/Eq	0.14	Earnings	May 08 BMO	SMA200	2.05%	Avg Volume	259.12K	Price	1.88
IPO	Apr 29, 2022	Option/Short	No / Yes	EPS/Sales Surpr.	67.12% -	Trades		Volume	149,251	Change	1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-24	Downgrade	Stifel	Buy → Hold	$34 → $3
Jul-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$28 → $2
Jul-09-24	Downgrade	H.C. Wainwright	Buy → Neutral	$28 → $2
Jul-08-24	Downgrade	JP Morgan	Overweight → Neutral	$24 → $5
Jul-08-24	Downgrade	Guggenheim	Buy → Neutral
Dec-13-23	Initiated	H.C. Wainwright	Buy	$28

May-08-25 07:00AM	HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Mar-28-25 05:00PM	HilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire) -8.81%
Nov-07-24 08:00AM	HilleVax Reports Third Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Oct-14-24 12:00PM	What Makes HilleVax (HLVX) a New Buy Stock (Zacks)
Aug-08-24 07:20PM	HilleVax Reports Second Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
11:53AM	Loading…
Aug-01-24 11:53AM	HilleVax slashes workforce by 40% after norovirus vaccine trial failure (Pharmaceutical Technology)
Jul-31-24 04:00PM	HilleVax Announces Reduction in Force (GlobeNewswire)
Jul-29-24 09:35AM	After Plunging -86.93% in 4 Weeks, Here's Why the Trend Might Reverse for HilleVax (HLVX) (Zacks)
Jul-11-24 09:35AM	Down -88.84% in 4 Weeks, Here's Why HilleVax (HLVX) Looks Ripe for a Turnaround (Zacks)
Jul-09-24 10:19AM	HilleVax (HLVX) Tanks as Norovirus Vaccine Study in Infants Fails (Zacks)
Jul-08-24 12:36PM	GRFS Stock Alert: Grifols Pops 20% on Takeover Interest (InvestorPlace) -88.34%
12:17PM	Why Is HilleVax (HLVX) Stock Down 87% Today? (InvestorPlace)
08:42AM	Takeda-spinout HilleVax sees stock sink 80% as norovirus vaccine flunks phase 2 trial in infants (FierceBiotech.com)
08:16AM	HilleVaxs norovirus vaccine ineffective in large trial of infants (BioPharma Dive)
07:30AM	HilleVax Reports Topline Data from NEST-IN1 Phase 2b Clinical Study of HIL-214 in Infants (GlobeNewswire)
02:15AM	Loading…
May-23-24 02:15AM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com) -7.50%
May-10-24 02:26PM	HilleVax Inc (HLVX) Reports Increased Q1 Losses, Misses Analyst Earnings Expectations (GuruFocus.com)
May-09-24 11:55PM	HLVX Stock Earnings: HilleVax Misses EPS for Q1 2024 (InvestorPlace)
04:05PM	HilleVax Reports First Quarter 2024 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-06-24 01:33AM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com)
Mar-21-24 02:32AM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com)
Mar-20-24 09:53PM	HLVX Stock Earnings: HilleVax Beats EPS for Q4 2023 (InvestorPlace) -7.57%
04:00PM	HilleVax Reports Full Year 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Mar-08-24 11:55PM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com)
Feb-22-24 11:27PM	Director Aditya Kohli Sells 18,000 Shares of HilleVax Inc (HLVX) (GuruFocus.com) +5.12%
Feb-05-24 04:05PM	HilleVax to Present at Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-18-24 07:00AM	HilleVax Announces Executive Management Appointment of Sean McLoughlin as Chief Operating Officer (GlobeNewswire)
Jan-08-24 07:00AM	HilleVax and Kangh Announce Exclusive License Agreement for Hexavalent VLP Norovirus Vaccine Candidate Outside of China (GlobeNewswire)
Jan-03-24 06:28PM	HilleVax to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
01:01PM	Loading…
Dec-19-23 01:01PM	Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ... (GuruFocus.com)
Dec-05-23 09:48PM	Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 20,000 Shares of HilleVax Inc ... (GuruFocus.com)
Nov-30-23 09:55AM	Wall Street Analysts Believe HilleVax, Inc. (HLVX) Could Rally 92.19%: Here's is How to Trade (Zacks)
Nov-21-23 11:03AM	Insider Sell Alert: Chief Medical Officer Astrid Borkowski Sells 10,000 Shares of HilleVax Inc ... (GuruFocus.com)
Nov-14-23 12:00PM	HilleVax, Inc. (HLVX) Moves to Buy: Rationale Behind the Upgrade (Zacks) +11.03%
09:55AM	Does HilleVax, Inc. (HLVX) Have the Potential to Rally 107.23% as Wall Street Analysts Expect? (Zacks)
Nov-09-23 04:05PM	HilleVax Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire) +6.18%
Nov-01-23 04:48PM	HilleVax to Present at Upcoming Investor Conferences (GlobeNewswire) +8.18%
Sep-26-23 04:01PM	HilleVax to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference (GlobeNewswire)
Sep-25-23 07:00AM	HilleVax Announces Closing of Public Offering of Common Stock and Full Exercise of the Underwriters Option to Purchase Additional Shares (GlobeNewswire)
Sep-19-23 08:05PM	HilleVax Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:09PM	HilleVax Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Aug-24-23 10:40AM	J.P. Morgan Sees up to 110% Gains in These 2 Stocks Heres Why They Could Soar (TipRanks)
Aug-14-23 05:08PM	Biotech behind 2022's largest local IPO delays norovirus vaccine (American City Business Journals) -7.26% -10.17%
07:00AM	HilleVax Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
Jun-07-23 09:55AM	Wall Street Analysts Predict a 56.76% Upside in HilleVax, Inc. (HLVX): Here's What You Should Know (Zacks)
May-22-23 09:55AM	How Much Upside is Left in HilleVax, Inc. (HLVX)? Wall Street Analysts Think 87.76% (Zacks)
May-12-23 04:05PM	HilleVax Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire)
May-09-23 07:00AM	HilleVax Announces Appointment of Nanette Cocero Ph.D., MBA, to its Board of Directors (GlobeNewswire)
Apr-25-23 06:45AM	HilleVax Announces Completion of Enrollment of NEST-IN1 Phase 2b Clinical Study of HIL-214 Norovirus Vaccine Candidate (GlobeNewswire)

HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. Its pipeline includes Norovirus and HIL-214. The company was founded by Maurice Hilleman and Tadataka Yamada on March 25, 2020 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HERSHBERG ROBERT	See Remarks	Feb 04 '25	Sale	1.89	14,634	27,658	1,113,399	Feb 12 04:05 PM
HERSHBERG ROBERT	See Remarks	Feb 11 '25	Sale	1.76	11,901	21,003	1,101,498	Feb 12 04:05 PM
Maltbie Shane	Chief Financial Officer	Feb 11 '25	Sale	1.76	4,345	7,659	79,887	Feb 12 04:05 PM
Maltbie Shane	Chief Financial Officer	Feb 04 '25	Sale	1.89	3,946	7,458	84,232	Feb 12 04:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HLVX

HilleVax Inc

Upgrade your FINVIZ experience